



Contents lists available at ScienceDirect

Journal of Traditional and Complementary Medicine

journal homepage: <http://www.elsevier.com/locate/jtcm>

Inonotus obliquus – from folk medicine to clinical use

Konrad A. Szychowski^{a,*}, Bartosz Skóra^a, Tadeusz Pomianek^b, Jan Gmiński^a

^a Department of Lifestyle Disorders and Regenerative Medicine, University of Information Technology and Management in Rzeszow, Sucharskiego 2, 35-225, Rzeszow, Poland

^b Department of Management, Faculty of Administration and Social Sciences, University of Information Technology and Management in Rzeszow, Sucharskiego 2, 35-225, Rzeszow, Poland

ARTICLE INFO

Article history:

Received 7 July 2020

Received in revised form

18 August 2020

Accepted 19 August 2020

Available online xxx

Keywords:

Inonotus obliquus

Anti-Cancer

Anti-inflammation

Mushroom

Anti-virus

ABSTRACT

The *Inonotus obliquus* (*I. obliquus*) mushroom was traditionally used to treat various gastrointestinal diseases. For many years, mounting evidence has indicated the potential of *I. obliquus* extracts for treatment of viral and parasitic infections. Furthermore, substances from *I. obliquus* have been shown to stimulate the immune system. The most promising finding was the demonstration that *I. obliquus* has hypoglycemic and insulin sensitivity potential. This review summarizes the therapeutic potential of *I. obliquus* extracts in counteracting the progression of cancers and diabetes mellitus as well as their antiviral and antiparasitic activities and antioxidant role. As shown by literature data, various authors have tried to determine the molecular mechanism of action of *I. obliquus* extracts. Two mechanisms of action of *I. obliquus* extracts are currently emerging. The first is associated with the broad-sense impact on antioxidant enzymes and the level of reactive oxygen species (ROS). The other is related to peroxisome proliferator-activated receptor gamma (PPAR γ) effects. This receptor may be a key factor in the anti-inflammatory, antioxidant, and anti-cancer activity of *I. obliquus* extracts. It can be concluded that *I. obliquus* fits the definition of functional food and has a potentially positive effect on health beyond basic nutrition; however, studies that meet the evidence-based medicine (EBM) criteria are needed.

© 2020 Center for Food and Biomolecules, National Taiwan University. Production and hosting by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1. Introduction

Inonotus obliquus (*I. obliquus*) (Ach. ex Pers.) Pilát, belonging to the family *Hymenochaetaceae*, is a black-brown plant parasitic fungus.^{1,2} This mushroom has also at least a few common and regional names such as [Pol.] czerniak brzozy, czyreń, czernidło, czarcie oko, or czanga, which most likely has been coined from the Russian word "chaga".³ The genus *Inonotus* is widespread in North America, Asia, and Europe and includes approximately 100 species.^{3,4} In Europe, this genus is represented only by 4 species, with *I. obliquus* as one of them.⁴ Although it is widely distributed in North America, Asia, and Europe, *I. obliquus* is on the list of partially

protected species of mushrooms in Poland.⁵

I. obliquus is a primary tree parasite causing decomposition of live trunks.⁶ It has been seen on many trees species such as alder, beech, maple, rowan, hornbeam, poplar, oak, ash, willow, plane-tree, chestnut, and walnut, but the main hosts of *I. obliquus* are various species of birch.^{3,7} It should be noted that the reports on the occurrence of *I. obliquus* on different species of deciduous trees are not reliable, because other fungi of the genus *Inonotus* are very often confused with the analyzed species.^{3,7}

I. obliquus infects approximately 30–50-year-old trees through wounds in the bark and can grow on the trunk for another 30–80 years.^{3,5} A few years after penetrating the trunk of live trees, it produces sclerotia (vegetative or asexual fruiting bodies) with a lumpy irregular shape, cracked surface, and black-brown color. The interior of the sclerotium itself is made of rust-brown, yellow-veined, very dense mycelium.³ The sclerotia grow very slowly, reaching a diameter of more than 10 cm after 10–15 years.⁵ On old trees, the growths can exceed 50 cm in diameter.³ After many years, the host tree dies and annual fruiting bodies of the sexual stage appear. Fruiting bodies of this stage develop in the warm season of

* Corresponding author. Department of Lifestyle Disorders and Regenerative Medicine, University of Information Technology and Management in Rzeszow, Sucharskiego 2, 35-225, Rzeszow, Poland.

E-mail addresses: kszychowski@wsiz.rzeszow.pl (K.A. Szychowski), bskora@wsiz.rzeszow.pl (B. Skóra), tpomianek@wsiz.rzeszow.pl (T. Pomianek), jgmiński@wsiz.rzeszow.pl (J. Gmiński).

Peer review under responsibility of The Center for Food and Biomolecules, National Taiwan University.

<https://doi.org/10.1016/j.jtcm.2020.08.003>

2225-4110/© 2020 Center for Food and Biomolecules, National Taiwan University. Production and hosting by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Abbreviations			
ABTS	2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)	IκBα	inhibitor kappa B alpha
ALT	alanine aminotransferase	LPS	lipopolysaccharides
AST	aspartate aminotransferase	MDA	malondialdehyde
Bax	Bcl-2-associated X protein B-cell	MMPs	matrix metalloproteinases
Bcl-2	B- cell lymphoma 2	NF-κB	nuclear factor kappa-light-chain-enhancer of activated B cells
CAT	catalase	NO	nitric oxide
COX-2	cyclooxygenase-2	Nrf2	nuclear factor erythroid 2-related factor 2
DPPH•	2,2-diphenyl-1-picrylhydrazyl	p-AKT	phospho-protein kinase B
GPx	glutathione peroxidase	PGE ₂	prostaglandin E ₂
H ₂ DCFDA	2',7'-dichlorodihydrofluorescein diacetate	PI3k	phosphatidylinositol 3-kinase
HCV	Hepatitis C Virus	p-mTOR	phospho-mammalian target of rapamycin
HO-1	heme oxygenase-1	PPARγ	peroxisome proliferator-activated receptor gamma
IFNγ	interferon gamma	ROS	reactive oxygen species
IL-12	interleukin 12	SOD	superoxide dismutase
IL-1β	interleukin 1 beta	STZ	streptozotocin
IL-2	interleukin 2	T2DM	type 2 diabetes mellitus
IL-4	interleukin 4	TGF-β	transforming growth factor beta
IL-6	interleukin 6	TIMPs	tissue metalloproteinase inhibitors
IL-10	interleukin 10	TLR2	toll-like receptor 2
iNOS	inducible nitric oxide synthase	TLR4	toll-like receptor 4
		TNFα	tumor necrosis factor alpha
		XOD	xanthine oxidase

the year in places with the most advanced rot. They very rarely grow on live trees.^{3,8} This type of fruiting bodies may have considerable sizes (up to 3–4 m in length and up to 50 cm in width) and are eaten very quickly by insects, which are assumed to be the main (besides the wind) spore-spreading vector of *I. obliquus*.³

Numerous scientific studies have shown that the some assumptions of folk medicine beliefs are reasonable. Mexican and European folk medicine plants have been tested on *in vivo* or *in vitro* models, e.g. *Jasminum fruticans*, *Mentha longifolia*, and *Artemisia absinthium* extracts, which show anthelmintic or antibacterial effects.^{9,10} Given these examples, the search for new potentially active, natural compounds in folk medicine extends the present knowledge and help to find a promising cure to such prevalent diseases as cancers, parasitic infestations, or bacterial infections. Therefore, the usefulness of *I. obliquus* extract in medicine, e.g. in the treatment of diabetes and parasitic and viral infections, was evaluated. However, there has been no work so far, presenting the current scientific findings on *I. obliquus* in a concise and substantive form. Therefore, the aim of this work is to present the current state of knowledge of the biological properties of the *I. obliquus* mushroom and the potential possibilities of its medical use.

2. Application of *I. obliquus* in folk medicine

In folk medicine, rational premises are intertwined with elements of magic. The rational premises are based on observation of the natural environment and finding substances that alleviate disease symptoms. In many countries, this is the only way in which people can improve their health due to poverty in society or difficult access to scientific medicine. *I. obliquus* has been used in folk medicine since ancient times. One of the oldest documents confirming the use of its conks for medicinal purposes is the work by Hippocrates "Corpus Hippocraticum".³ The father of medicine used infusions of this mushroom externally to wash wounds.

In Eastern Europe, the Chaga mushroom has been used since the 12th century. Historical sources describe healing of a lip tumor in a Kiev Kniaz.¹¹ *I. obliquus* was used in traditional medicine for many indications by the people of Siberia.¹² The fungus was applied due

to its antiparasitic, anti-tuberculosis, anti-inflammatory, and gastrointestinal properties.¹³ It was also recommended for heart and liver diseases. Most often, it was used in the form of infusions, inhalations, or aqueous macerates.¹³ Also antiseptic soaps containing *I. obliquus* were prepared for external use. In the middle of the 20th century, Chaga infusions were used as a substitute for tea in Siberia.¹⁴ Relatively early attention was paid to the potential *I. obliquus* antitumor or supportive effect in cancer treatment, which was particularly important before the era of scientific oncology. Such descriptions can be found in popular literature, e.g. in Aleksander Solzhenitsyn's Cancer Ward.¹⁴

In Asia (China, Japan, Korea), Russia, and the Baltic countries, extracts of Chaga mushroom were used due to their beneficial effects on the plasma lipid system and heart function as well as antibacterial, anti-inflammatory, and anti-cancer activity.¹⁵ Furthermore, the antioxidant activity of *I. obliquus* may be important for prevention of free radical-related civilization diseases (atherosclerosis, cancer, diabetes, accelerated aging, and degenerative diseases of the central nervous system).¹⁶ Chaga extracts have been shown to inhibit the reproduction of hepatitis C virus (HCV) and human immunodeficiency viruses (HIV).¹⁷

The only objective method to assess the effectiveness of any therapy in scientific medicine is to perform research that meets the criteria of evidence-based medicine (EBM). Unfortunately, no observations from folk medicine or folk tales meet these criteria. Therefore, while drawing information from these sources, it is necessary to conduct scientific research that will either refute or confirm the folk premises. Importantly, the highest EBM standards should be maintained during the research, giving grounds for verifying folk knowledge.

3. Chemical composition and approaches to extraction of substances from *I. obliquus*

Only young and fresh sclerotia growing on birches, harvested throughout the year, are used in medicine.³ Sclerotia should be harvested in uncontaminated areas distant from sources of pollution, which may accumulate in the fungus.¹⁸ In the natural

Table 1

Approaches to isolation and administration of extracts or various substances isolated from *Inonotus obliquus*.

TYPES OF EXTRACTS FROM <i>Inonotus obliquus</i> TESTED	REFERENCES
ENTIRE WATER EXTRACTS	28,30,31,39,41–45
ENTIRE ETHANOL EXTRACTS	1,30,36,41,42,46–48
ENTIRE METHANOL EXTRACTS	30,32,41,49
ENTIRE SODIUM HYDROXIDE EXTRACTS	41
ENTIRE CYCLOHEXANE EXTRACTS	31
ENTIRE ETHYL ACETATE EXTRACTS	31
MELANIN FRACTION	24,29,50
INODOTIOL FRACTION	33,51
FLAVAN FRACTION	34
TRITERPENOID AND STEROIDS FRACTIONS	1,35,52–54
POLYSACCHARIDE FRACTIONS	1,37,62–69,38,55–61
POLYPHENOLIC FRACTION	1,32,36,70

environment, *I. obliquus* grows in a cool climate with high seasonal temperature fluctuations, freezing, UV radiation, as well as occurrence of bacterial and viral infections.^{19,20} In response to numerous stressors, *I. obliquus* has developed complex defense mechanisms. These mechanisms include the production of various bioactive substances: antioxidants, triterpenoids, ergosterol and its peroxide, sesquiterpenes, benzoic acid derivatives, hispidin analogues, and melanins. In addition, high expression of antioxidant enzymes has been detected in *I. obliquus*.^{21–26} Moreover, many reports have highlighted that the polysaccharide fraction present in *I. obliquus* extracts is the largest group of active compounds, besides phenols. Therefore, many investigations have been performed to evaluate the polysaccharide content in this mushroom extracts, also in various conditions of extraction such as freeze, hot air, or vacuum drying methods.²⁷ As reported by Ma et al. *I. obliquus* extracts contain many low molecular polysaccharides, which are considered antioxidant agents responsible for this activity of these mentioned extracts.²⁷ This antiradical property has been repeatedly proved in the literature *inter alia* by Ma et al. or Cui et al. who tested the antioxidant properties of *I. obliquus* saccharides *in vitro* or *in vivo* on rat livers, respectively.^{1,27} The water extract contained 19.76–26.51% of neutral sugars, in which the sugar composition varied depending on the drying method, but rhamnose, galactose, and glucose were the dominant sugars, whereas arabinose or mannose were the least abundant components.²⁷ The chemical structure of *I. obliquus* polysaccharides was also strictly related to the method applied, indicating that the saccharides were characterized by a dense spherical, branching, and elongated rod structure.²⁷

Currently, many approaches for isolation of substances from *I. obliquus* have been described; they are summarized in Table 1. They can be divided into techniques yielding the whole of isolated substances, individual fractions, or even single active substances from *I. obliquus*.^{1,28,29} The use of total aqueous or ethanol extracts is the most similar approach to the methods used in folk medicine.^{28,30} These types of extracts are suitable for direct consumption. Unfortunately, the application of other methods of total extraction using organic solvents such as methanol, ethyl acetate, or cyclohexane prevents the use of such a product.^{30–32} From a practical point of view, the use of a whole extract in scientific research is very important for practical natural or herbal medicine. In addition, many substances present in the whole extract can abolish or enhance each other's activity. On the other hand, it is not possible to investigate the exact mechanism of specific substances in a non-fractionated extract. Another approach is to use individual fractions obtained from *I. obliquus*. In the literature, there are descriptions of research on various substances isolated from *I. obliquus*, including melanin, inodotiol, flavans, triterpenoids, steroids, polyphenols, or polysaccharides.^{1,24,33–36} This type of

approach makes it possible to determine precisely which substance has therapeutic effects. Currently, the most frequently performed research is focused on the polysaccharide fraction (summarized in Table 1). As shown in the literature, this is a very promising group of substances associated with anti-cancer activity and insulin-improving sensitivity.^{37,38} It should be noted that proteins contained in extracts are not studied. The extraction methods denature the protein at an early stage of isolation. In the case of aqueous extracts, the isolation of the substance is carried out at a temperature between 80 and 100 °C.^{37,39,40} Similarly, various organic solvents (ethanol, methanol, cyclohexane, etc.) as well as multi-stage extraction methods can destroy the bioactive active ingredients contained in *I. obliquus*.

4. Biological properties of *Inonotus obliquus* extracts

Many different properties of extracts or substances derived from *I. obliquus* have been described to date. These include antiviral, antidiabetic, antioxidant, antiparasitic, immunomodulatory, anti-inflammatory, neuroprotective, anticancer properties *in vitro*, and recently antifatigue effects.^{1,30,36,37,39,65,71} Relevant literature data are summarized in Table 2.

4.1. Antioxidant properties

The antioxidant properties of extracts and individual fractions of substances obtained from *I. obliquus* are the most frequently studied parameter in scientific publications. To determine the antioxidant potential, methods based on the stable 2,2-diphenyl-1-picrylhydrazyl radical (DPPH•) are used.^{1,57,61,77,85,96–98} Less often, another stable 2,2'-azino-bis (3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) radical is used.^{70,79} The DPPH• and ABTS methods are based only on the antioxidant properties of chemical substances and do not fully reflect the antioxidative potential of a given extract or substance.^{99,100} Methods based on the impact on the activity or expression of antioxidant enzymes as well as the formation of reactive oxygen species (or scavenging) in living cells reflect better the actual state in the organism. To date, the effects of *I. obliquus* extracts on the activity and/or expression of antioxidant enzymes such as superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), xanthine oxidase (XOD) in cell cultures and mouse tissues have been described.^{30,37,55,57,59,66,78} In addition, extracts from *I. obliquus* affected reactive oxygen species (ROS) production measured with the malonic dialdehyde (MDA) and 2',7'-dichlorodihydrofluorescein diacetate (H₂DCFDA) methods.^{58,63,92} Interestingly, the effects were different depending on the type of cell. Szychowski et al. showed that extracts from *I. obliquus* reduced the amount of ROS in normal cells^{30,58}; in turn, numerous research teams described an increase in ROS in cancer cell lines.^{30,67}

Flavan derivatives, polysaccharides, and 3,4-dihydroxybenzalacetone isolated from *I. obliquus* have also been shown to have neuroprotective effects in neurodegenerative disease models such as Alzheimer and Parkinson diseases and the SH-SY5Y cell line.^{34,66,92} These substances were found to protect against oxidative stress or increase SOD expression. Similarly, in other cells considered normal, such as pancreatic (RINm5F cell line) and hepatic (LO2 cell line) cells, *I. obliquus* polysaccharides protected against H₂O₂-induced damage.^{42,58,77}

4.2. Anti-inflammatory and immunomodulatory effects

So far, few research teams have tried to determine the impact of extracts obtained from *I. obliquus* on the immune system.^{33,88,89} Fan et al. have shown that water-soluble polysaccharides obtained from

Table 2
Properties of different extracts from *Inonotus obliquus*. *In vitro* means a cell culture model or chemical analysis (cell-free model) *in vivo* means experiments performed on animals. To date, no human experiments have been performed.

PROPERTIES OF DIFFERENT EXTRACTS FROM <i>Inonotus obliquus</i>	TYPE OF BIOLOGICAL MODEL USED	REFERENCES
ANTIVIRAL	<i>in vivo</i>	17,39,72–74
ANTIDIABETIC	<i>in vivo/in vitro</i>	29,37,55,56,75,76
ANTIOXIDANT/ROS SCAVENGER	<i>in vivo/in vitro</i>	1,30,59,60,70,75,77–82,36,83–87,37,42,50,55–58
ANTIFATIGUE	<i>in vivo</i>	71
ANTIPARASITIC	<i>in vivo</i>	63–65
IMMUNOMODULATORY	<i>in vivo/in vitro</i>	33,48,61,62,64,88–90
ANTI-INFLAMMATORY	<i>in vivo/in vitro</i>	33,36,41,57,86,91
NEUROPROTECTIVE	<i>in vivo/in vitro</i>	34,66,82,92
ANTI-CANCER POTENTIAL	<i>in vitro</i>	28,30,49,51,63,67,75,93–95,31,32,38,43–47

I. obliquus increased the proliferation of murine peritoneal lymphocytes.³⁸ Polysaccharides from *I. obliquus* also stimulated the production of tumor necrosis factor-alpha (TNF α) by mouse macrophages. TNF α production increased in direct proportion to the increasing concentration of the tested polysaccharides.³⁸ Similarly, Chen et al.¹⁰¹ observed that polysaccharides from *I. obliquus* increased the proliferation of splenocytes and lymphocytes. In addition, *I. obliquus* increased the secretion of cytokines such as interleukin-2 (IL-2), interleukin-6 (IL-6), interleukin-12 (IL-12), and TNF α and intensified the phagocytic processes. *I. obliquus* also significantly increased Bax expression and inhibition of Bcl-2.¹⁰¹ In turn, the latest research has shown that *I. obliquus* extracts very strongly reduced TNF α secretion in the RAW 264.7 cell line.⁴¹ Similarly, Chen et al. showed that polysaccharides from *I. obliquus* affected the Th1/Th2 lymphocyte ratio and Th17/Treg in the colon, mesenteric lymph nodes, and spleen of male BALB/c mice.⁸⁹ Using a mouse model, the authors showed that the studied polysaccharides from *I. obliquus* could be used to treat inflammatory bowel disease. Other studies performed on BALB/c mice showed that extracts from *I. obliquus* suppressed Th2 and Th17 immune response.³³ It is currently thought that *I. obliquus* extracts or their polysaccharide fraction inhibit inflammatory reactions.^{41,57} Most studies show a reduction in the production and/or secretion of proinflammatory cytokines such as interleukin-1 beta (IL-1 β), interferon gamma (IFN γ), and TNF α .^{41,57,89} *In vivo* studies showed that an *I. obliquus* extract administered to Sprague-Dawley rats for 7 days protected the animals against the development of induced inflammation. The same studies showed that the *I. obliquus* extract exhibited analgesic properties as well.¹⁶ Park et al. tried to elucidate the mechanism of the anti-inflammatory and analgesic effects of *I. obliquus* extracts on the RAW 264.7 cell line.¹⁶ It was demonstrated that the extract caused a decrease in the production of nitric oxide (NO) and prostaglandin E₂ (PGE₂).¹⁶ In addition, LPS-stimulated macrophages produced nitric oxide synthase (iNOS), which was inhibited by the *I. obliquus* extract. Furthermore, the tested extract inhibited lipopolysaccharide (LPS)-induced cyclooxygenase-2 (COX-2) production.¹⁶ The *I. obliquus* extract also reduced mRNA production and expression of TNF α and the nuclear factor kappa-light-chain-enhancer of activated B cells (NF- κ B) induced by LPS.¹⁶ Recent studies have shown that individual fractions from *I. obliquus* can act antagonistically. Wold et al. proved that some polysaccharide fractions increased NO production by murine macrophage and dendritic cell lines J774, A1 and D2SC/1.⁶² It cannot be excluded that, depending on the type of cells tested, the extracts or individual substances from *I. obliquus* may increase or inhibit NO production.

4.3. Antiviral, antibacterial, and antiparasitic properties of *I. obliquus*

Data on the antiviral activity of *I. obliquus* extracts are very

limited. To date, it has been shown that polysaccharides derived from the aqueous fraction of *I. obliquus* inhibit the protease from HIV type 1 (HIV-1), and thus impede the entry of virions into cells.³⁹ In other studies, Shibnev et al. showed that the *I. obliquus* water extract was active against the HCV.¹⁷ At 48 h after addition of the *I. obliquus* aqueous extract to the HCV-infected embryonic porcine kidney epithelial inoculated line (SPEV), the amount of the virus in the cells was inversely proportional to the concentration of the added extract. At the highest concentrations, the extract completely stopped or significantly inhibited the reproduction of HCV. Moreover, it was shown that the addition of the extract to the cells 24 h before their exposure to the virus protected the SPEV cells from infection.¹⁷ In another experiment, an aqueous extract of *I. obliquus* showed an effect against the herpes virus - Herpes simplex type 1 (HSV-1) in normal kidney cells (Vero) of infected *Cercopithecus aethiops*.¹⁰² The presented studies confirm the antiviral effect of *I. obliquus* and indicate its potential use in the treatment of diseases associated with viral infections. In addition, the polysaccharide fraction of *I. obliquus* exhibited a broad-spectrum antiviral activity against feline herpesvirus 1, feline influenza virus H3N2 and H5N6, feline panleukopenia virus, and feline infectious peritonitis virus, which cause respiratory and gastrointestinal diseases in cats.⁷³ Similarly, Seo and Choi showed that ethanolic extracts from *I. obliquus* inhibited the entry of murine norovirus (MNV) and feline calicivirus (FCV) into RAW264.7 cells.⁷²

In the available literature, there are only two reports suggesting the antibacterial or probiotic effect of *I. obliquus* extracts. Niu et al. showed that various fractions derived from *I. obliquus* stimulated NO production and additionally increased phagocytosis in RAW 264.7 cells.⁶¹ As demonstrated by Hu et al. *I. obliquus* polysaccharide was found to regulate the gut microbiota in chronic pancreatitis in mice.¹⁰³ Moreover, the authors suggest that administration of *I. obliquus* polysaccharides could regulate the gut microbiota composition and diversity to a healthy profile in mice with chronic pancreatitis.

To date, only one team has studied the antiparasitic aspects of *I. obliquus* extracts and polysaccharides.^{63–65} *Toxoplasma gondii* (*T. gondii*) is an obligate intracellular protozoan that causes toxoplasmosis in humans and many warm-blooded animals. Approximately 30%–50% of the population is infected with *T. gondii* worldwide.¹⁰⁴ Xu et al. described that *I. obliquus* polysaccharides significantly reduced the abortion rate, inhibited the decreases in progesterone (P) and estradiol (E₂) levels and the increase in the MDA level, and increased the activities of SOD and GSH.⁶⁴ Furthermore, *I. obliquus* polysaccharides inhibited the production of inflammatory cytokines, such as TNF α , IL-6, IFN γ , IL-1 β , and IL-17A, and promoted the production of the anti-inflammatory cytokine interleukin-10 (IL-10) and transforming growth factor (TGF)- β in *T. gondii*-infected pregnant mice.⁶⁴ Similarly, Xu et al. described that *I. obliquus* polysaccharides significantly decreased the liver coefficient and the levels of alanine aminotransferase (ALT),

Table 3Anti-cancer potential of extracts or substances isolated from *Inonotus obliquus* tested on different tumor cell lines.

CANCER CELL LINE	ASSAYS	REFERENCES
A549 human lung adenocarcinoma	LDH release	28,95
	Caspase-3 activity	67,95
	DNA fragmentation	
	Cell viability	28,32,49,67,68,95
	Cell migration	28
	Cell proliferation	
	ROS production	67
	Cytotoxicity	31
	Cell viability	49,51
	Caspase-3 activity	51
HeLa human cervical cancer	Cell migration	
	Cell viability	47
	Cell viability	47,49,68
4T1 mouse mammary carcinoma	Cell viability	49
MCF-7 human breast cancer	Cell viability	49
AGS human gastric cancer	Cell viability	49
HEK-293 human embryonic kidney	Cell viability	32
PA-1 human ovarian teratocarcinoma	Cell viability	32
U937 human myeloid leukemia cell	Cell viability	32
HL-60 human myeloid leukemia	Cell viability	30
CACO-2 human colon carcinoma	Cell viability	
	LDH release	
	ROS production	
	Cell proliferation	
	Cell viability	28,46
HT-29 human colorectal adenocarcinoma	DNA synthesis	
	Cell proliferation	
	LDH release	28
	Cell migration	
	LDH release	95
H1264 lung adenocarcinoma	LDH release	
	Caspase-3 activity	
	DNA fragmentation	
	Cell viability	45
	Cell viability	
HCT-116 human colon carcinoma	LDH release	
	Caspase-3 activity	
	LDH release	95
H1299 human non-small cell lung cancer	Caspase-3 activity	
	DNA fragmentation	
	Cell viability	
	Cell viability	44,68,93
	Caspase-3 activity	44
B16-F10 murine skin melanoma	Cell cycle inhibition	
	Cell migration	93
	LDH release	95
	Caspase-3 activity	
Calu-6 human pulmonary adenocarcinoma	DNA fragmentation	
	Cell viability	
	Cell viability	68
	Caspase-3 activity	94
	Cell viability	
HEC-1B human endometrial adenocarcinoma	DNA fragmentation	
	Cell viability	
	Cell viability	28
	Cell proliferation	
	LDH release	
P388 mouse leukemia	Cell migration	
	LDH release	
	Cell migration	
	LDH release	
	Cell migration	
Fao rat hepatoma	Cell viability	28
	Cell proliferation	
	LDH release	
	Cell migration	
	Cell viability	28
P19 mouse embryo teratocarcinoma	Cell proliferation	
	LDH release	
	Cell migration	
	Cell viability	28
	Cell proliferation	
C6 rat glioma	LDH release	
	Cell migration	
	Cell viability	28
	Cell proliferation	
	LDH release	
Hep3B human hepatoma	Cell migration	
	Cell viability	43,107
	Cell cycle inhibition	43
HepG2 human hepatoma	Cell viability	43,107
	Cell cycle inhibition	43
	ROS production	108
	Cell viability	68
	Cell viability	68
Hur7 human hepatoma	Cell viability	68
KATO-III human stomach carcinoma	Cell viability	40
DLD-1 human colon carcinoma	DNA fragmentation	38
SGC-7901 human gastric carcinoma	Cell viability	68
SK-OV3 human ovary adenocarcinoma	Cell viability	
SW156 kidney adenocarcinoma	Cell viability	68
SW620 human colorectal adenocarcinoma	Cell proliferation	105




Fig. 1. Proapoptotic and antioxidant action of *Inonotus obliquus* extracts in normal and neoplastic cells described in literature.

aspartate aminotransferase (AST), MDA, and nitric oxide NO. In turn, the polysaccharides increased the levels of antioxidant enzymes SOD and GSH.⁶³ As mentioned previously, *I. obliquus* polysaccharides also effectively decreased the expression of serum TNF α , IL-6, IL-1 β , IFN γ , and interleukin-4 (IL-4) in *T. gondii*-infected mice. The authors found that *I. obliquus* polysaccharides down-regulated the levels of toll-like receptor 2 (TLR2) and toll-like receptor 4 (TLR4) and phosphorylation of NF- κ B p65 and inhibitor kappaB α (I κ B α), but up-regulated the expression of nuclear factor erythroid 2-related factor 2 (Nrf2) and heme oxygenase-1 (HO-1).⁶³ Lastly, Ding et al. showed that *I. obliquus* polysaccharides significantly improved the spermatogenic capacity, ameliorated pathological damage to testis, and increased the levels of serum testosterone, luteinizing hormone, and follicular-stimulating hormone in *T. gondii*-infected male mice. *I. obliquus* polysaccharides effectively up-regulated the expression of testicular steroidogenic acute regulatory protein (StAR), P450scc, and 17 β -HSD. These compounds further enhanced testicular phosphatidylinositol 3-kinase (PI3K), phospho-protein kinase B (*p*-AKT), and phosphomammalian target of rapamycin (*p*-mTOR) expression levels.⁶⁵

4.4. Anti-cancer potential

In medical databases, there are many publications on the anti-cancer activity of *I. obliquus* extracts *in vitro*. The anti-cancer potential of the extracts or substances isolated from *I. obliquus* and tested on different tumor cell lines are described in Table 3. Unfortunately, studies on animals are very limited and there are no reliable publications on humans.^{57,105} Most studies have been conducted on cell lines originating from the digestive system, such as AGS, HCT-116, HT-29, SW620, SGC-7901, DLD-1, and CACO-2^{30,38,46,105}. Extracts from *I. obliquus* have been shown to inhibit proliferation and/or are cytotoxic to these human gastrointestinal tumor cell lines. Similarly, their cytotoxic, anti-proliferative, or proapoptotic effects have been demonstrated in cell lines from many other tissues and systems, e.g. lung, cervix, mammary gland, ovary, liver, lymphoid cancers (A549, MCF-7, HepG2, HepG3B, HeLa, MCF-7, HL-60, PA-1, H1264, H1299) (described in detail in Table 3).^{28,32,43,49,94,95,106}

Unfortunately, many of these studies lack in-depth experiments. In some publications, the authors have limited themselves to reporting whether a given extract is toxic to cells without

elucidation of the molecular mechanism of action, using only one parameter. These include investigations of 4T1, MCF-7, AGS, HEK-293, PA-1, U937, HL-60, P388, Hur7, HEC-1B, KATO-III, SG-7901, SK-OV3, and SW156 cell lines.^{32,38,47,49,68} Interestingly, the majority of studies were conducted on the A549 line, which is a human lung adenocarcinoma line with the best documented anti-cancer potential of *I. obliquus* extracts or fractions of substances derived from the extract.^{28,31,67,68,95} In publications elucidating the molecular mechanism of extracts, the authors consistently emphasize the role of ROS in the mechanism of action of substances derived from *I. obliquus*.^{28,30} The authors also agree that extracts from *I. obliquus* intensify the process of apoptosis measured by caspase-3 activity or the level of DNA fragmentation and stop the cell cycle in the G0 phase.^{44,95,109} Very important in migration/metastasis of tumors are matrix metalloproteinases (MMPs).¹¹⁰ Interestingly, it has been shown that, although the *I. obliquus* extract was not toxic to the A549 cell line at low concentrations, it statistically significantly reduced cell migration.¹¹¹ The authors attributed this effect to the declining MMP-2 and MMP-9 expression and the increasing expression of tissue metalloproteinase inhibitor-2 (TIMP-2) as well as the reduced expression of NF- κ B.¹¹¹ Similarly, a decrease in NF- κ B expression in A549 induced by *I. obliquus* extracts has been described.¹⁰⁹ Moreover, it has been reported that *I. obliquus* polysaccharides inhibit the expression of MMP-2, MMP-7, and MMP-9 in B16-F10 mouse cells.⁹³ Recently, Zhang et al. described that inotodiol from *I. obliquus* decreases the expression of MMP-2 and MMP-9 in HeLa human cells and reduces cell invasiveness.⁵¹ Unfortunately, the tests performed *in vivo* are very limited. To date, it has been shown that tumors of the 3LL mouse lung cancer line implanted in C57BL/6 mice developed significantly more slowly in animals treated with an *I. obliquus* aqueous extract. In the experiment, it was shown that the tumor in mice receiving the extract was by 60% smaller and the number of metastases decreased by 25%. Interestingly, ingestion of *I. obliquus* reduced the body weight of the mice and increased their body temperature, which may have contributed to the protection against cancer, as suggested by the researchers.¹¹² Furthermore, *I. obliquus* extracts have been shown to inhibit the development of two tumor lines: melanoma B16-F10 and sarcoma-180 after implantation into Balbc/c strain mice.^{44,49} It has also been shown that ergosterol isolated from *I. obliquus* inhibited the development of human colorectal cancer in the C57BL/6 mouse strain.¹⁰⁵ It is currently believed that the high




Fig. 2. Antidiabetic and anti-inflammatory action of *Inonotus obliquus* extracts with key involvement of the PPAR_γ receptor described in literature.

content of polysaccharides is responsible for the anti-cancer potential of *I. obliquus*.^{67,111} However, the anti-cancer potential have been found in all types of extracts used.¹¹³

4.5. Hypoglycemic and insulin sensitivity action

ROS play a key role in many signaling pathways. Moreover, the relationship between oxidative stress and metabolic disorders such as type 2 diabetes (T2DM), cancer, obesity, and cardiovascular disease is well described.¹¹⁴ To date, it has been shown that *I. obliquus* polysaccharides have hypoglycemic activity.^{115,116} Unfortunately, the exact mechanism of action has not been elucidated. It has been described that *I. obliquus* polysaccharides in streptozotocin (STZ)-induced diabetic Wistar rats reduced blood glucose levels and restored the structure of β-cells after diabetes-induced cellular damage.¹¹⁷ *I. obliquus* polysaccharides lowered the level of lipid peroxidation products (such as low-density lipoprotein), whereas the high-density lipoprotein cholesterol level was enhanced.¹¹⁷ Moreover, Wang et al. reported that *I. obliquus* polysaccharides enhanced the serum levels of insulin and alleviated the metabolic derangement of glucose enzymes in STZ-induced diabetic mice.⁵⁶ In the same experimental model, *I. obliquus* polysaccharides with the chromium (III) complex significantly decreased fasting blood glucose levels, plasma insulin levels, and body weight in mice.⁵⁵ This is consistent with the previously described studies of total extracts. Cha et al. demonstrated that *I. obliquus* dietary treatment lowered serum glucose and leptin levels and alleviated obesity-related complications in T2DM OLETF rats.¹¹⁸ Similarly, Sun et al. described that feeding the experimental mice with *I. obliquus* improved serum insulin levels, moderately expanded the pancreatic islets, and reduced pancreatic injuries in alloxan-induced diabetic mice.¹¹⁹ In turn, *I. obliquus* polysaccharides elevated insulin levels in C57BL/6 mice with diabetic nephropathy; however, the cholesterol and triglyceride levels remained unaffected.¹²⁰ Recently, *I. obliquus* polysaccharide has been reported to help to alleviate pancreatic acinar atrophy and weight loss in chronic pancreatitis mice induced by diethylthiocarbamate. Hu et al. postulated that *I. obliquus* polysaccharides possessed strong antioxidant activity for scavenging free radicals *in vitro* and *in vivo*, which could be beneficial for chronic pancreatitis therapy in mice.⁵⁷

Peroxisome proliferator-activated receptor gamma (PPAR_γ) is a key receptor involved in insulin resistance and cell sensitivity to this hormone.¹²¹ Moreover, PPAR_γ is also involved in anti-

inflammatory action, by controlling activation and expression of NF-κB and pro-inflammatory cytokines.¹²² However, only one paper showed that *I. obliquus* extract activated adipogenesis of 3T3-L1 preadipocytes, enhanced the expression PPAR_γ target genes, and increased triacylglycerol accumulation.¹²³

5. Conclusions and perspectives

For decades, extracts of *I. obliquus* have been used as a remedy for numerous diseases in folk medicine. Recent discoveries have provided evidence of the appropriateness of using these drugs *in vitro*. Extracts from *I. obliquus* prepared in various solvents as well as individual fractions of substances derived from the fungus show antiviral, antibacterial, immunostimulating, and anti-tumor activity *in vitro*. To date, various studies have suggested significant therapeutic potential of substances derived from *I. obliquus*. Based on the literature data, it can be concluded that the effectiveness of extracts and/or substances derived from *I. obliquus* is based on two main mechanisms. The first one is the effect of *I. obliquus* on the production of ROS and/or on mechanisms of ROS scavenging, which varies depending on the cell type. The proposed scheme of the effect is described in Fig. 1.

The other mechanism is based on the action *via* the PPAR_γ receptor. Experimental evidence suggests that extracts and/or substances obtained from *I. obliquus* may affect the level of expression or activity of the PPAR_γ receptor.¹²³ In this way, extracts from *I. obliquus* can reduce insulin resistance. However, it cannot be excluded that the anti-cancer mechanism of action of *I. obliquus* extracts also involves the PPAR_γ receptor. The proposed scheme of the effects is described in Fig. 2. Unfortunately, due to the lack of data on the involvement of the PPAR_γ receptor in the anti-tumor activity of *I. obliquus* extracts, further research is required. It can be concluded that *I. obliquus* fits the definition of functional food and has a potentially positive effect on health beyond basic nutrition; however, studies that meet the EBM criteria are needed. Taking the above into account, we suppose that the *I. obliquus* extracts can be included in cancer therapies in the future; however, more specialistic analysis should be performed, especially on *in vivo* models.

CRedit authorship contribution statement

Konrad A. Szychowski: Data curation, Formal analysis, Writing - original draft. **Bartosz Skóra:** Writing - original draft. **Tadeusz**

Pomianek: Writing - original draft. **Jan Gmiński:** Writing - original draft.

Declaration of competing interest

The authors declare that there is no conflict of interest.

Acknowledgements

This work was supported by statutory funds from the University of Information Technology and Management in Rzeszow, Poland (DS 507-03-01 GW). The authors declare no conflict of interests.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.jtcme.2020.08.003>.

References

- Cui Y, Kim D-SS, Park K-CC. Antioxidant effect of *Inonotus obliquus*. *J Ethnopharmacol*. 2005;96(1-2):79–85. <https://doi.org/10.1016/j.jep.2004.08.037>.
- Dai YC. Polypore diversity in China with an annotated checklist of Chinese polypores. *Mycoscience*. 2012;53(1):49–80. <https://doi.org/10.1007/s10267-011-0134-3>.
- Szczepkowski A, Piętko J, Grzywacz A. [Biology and medicinal properties of the chaga mushroom *Inonotus obliquus* (Fr.) Pilát]. *Sylvan*. 2013;157(3):223–233.
- Wagner T, Fischer M. Natural groups and a revised system for the European poroid Hymenochaetales (Basidiomycota) supported by nLSU rDNA sequence data. *Mycol Res*. 2001;105(7):773–782. <https://doi.org/10.1017/S0953756201004257>.
- Zheng W, Miao K, Liu Y, et al. Chemical diversity of biologically active metabolites in the sclerotia of *Inonotus obliquus* and submerged culture strategies for up-regulating their production. *Appl Microbiol Biotechnol*. 2010;87(4):1237–1254. <https://doi.org/10.1007/s00253-010-2682-4>.
- Manka K, Sobiczewski P, Manka M, Fiedorow Z. *Fitopatologia Lesna*. Warszawa: Państwowe Wydawnictwo Rolnicze i Lesne; 2005.
- Ryvarden L, Gilbertson R, Eide A. European Polypores: Part 2: Meripilus-Tyromyces. In: *Synopsis fungorum*. 7. Oslo: Fungiflora; 1994.
- Cha JY, Lee SY, Lee SY, Chun KW. Basidiocarp formation by *Inonotus obliquus* on a living paper birch tree. *For Pathol*. 2011;41(2):163–164. <https://doi.org/10.1111/j.1439-0329.2010.00687.x>.
- Kozan E, Kùpeli E, Yesilada E. Evaluation of some plants used in Turkish folk medicine against parasitic infections for their in vivo anthelmintic activity. *J Ethnopharmacol*. 2006;108(2):211–216. <https://doi.org/10.1016/j.jep.2006.05.003>.
- Aghapoor K, Mohsenzadeh F, Shakeri A, Darabi HR, Ghassemzadeh M, Neumueller B. Catalytic application of recyclable silica-supported bismuth (III) chloride in the benzo [N, N]-heterocyclic condensation. *J Organomet Chem*. 2013;743:170–178.
- Perevedentseva L. Use of wild-growing mushrooms for therapeutic purposes in the perm territory, Russia. *Indian J Environ Health*. 2013;2(4):236–242.
- Harpe J de La. *Abrégé de l'Histoire Générale Des Voyages Continué Par Comeiras*. 1801.
- Saar M. Fungi in khanty folk medicine. *J Ethnopharmacol*. 1991;31(2):175–179. [https://doi.org/10.1016/0378-8741\(91\)90003-V](https://doi.org/10.1016/0378-8741(91)90003-V).
- Solženicyñ A. *Le pavillon des cancéreux roman*. 2007.
- Shashkina MY, Shashkin PN, Sergeev AV. Chemical and medicobiological properties of chaga. *Pharm Chem J*. 2006;40(10):560–568. <https://doi.org/10.1007/s11094-006-0194-4> (review).
- Park Y-MM, Won J-HH, Kim Y-HH, Choi J-WW, Park H-JJ, Lee K-TT. In vivo and in vitro anti-inflammatory and anti-nociceptive effects of the methanol extract of *Inonotus obliquus*. *J Ethnopharmacol*. 2005;101(1-3):120–128. <https://doi.org/10.1016/j.jep.2005.04.003>.
- Shibnev VA, Mishin DV, Garaev TM, Finogenova NP, Botikov AG, Deryabin PG. Antiviral activity of *Inonotus obliquus* fungus extract towards infection caused by hepatitis C virus in cell cultures. *Bull Exp Biol Med*. 2011;151(5):612–614. <https://doi.org/10.1007/s10517-011-1395-8>.
- Shashkina MY, Shashkin PN, Sergeev AV. Chemical and medicobiological properties of chaga. *Pharm Chem J*. 2006;40(10):560–568. <https://doi.org/10.1007/s11094-006-0194-4> (review).
- Bolwell PP, Page A, Pislewska M, Wojtaszek P. Pathogenic infection and the oxidative defences in plant apoplast. *Protoplasma*. 2001;217(1-3):20–32. <https://doi.org/10.1007/BF01289409>.
- Zucconi L, Ripa C, Selbmann L, Onofri S. Effects of UV on the spores of the fungal species *Arthrotrichy oligospora* and *A. ferox*. *Polar Biol*. 2002;25(7):500–505. <https://doi.org/10.1007/s00300-002-0371-1>.
- Taji S, Yamada T, Wada S ichi, Tokuda H, Sakuma K, Tanaka R. Lanostane-type triterpenoids from the sclerotia of *Inonotus obliquus* possessing anti-tumor promoting activity. *Eur J Med Chem*. 2008;43(11):2373–2379. <https://doi.org/10.1016/j.ejmech.2008.01.037>.
- Nakajima Y, Sato Y, Konishi T. Antioxidant small phenolic ingredients in *Inonotus obliquus* (persoon) Pilat (Chaga). *Chem Pharm Bull (Tokyo)*. 2007;55(8):1222–1226. <https://doi.org/10.1248/cpb.55.1222>.
- Lee IK, Kim YS, Jang YW, Jung JY, Yun BS. New antioxidant polyphenols from the medicinal mushroom *Inonotus obliquus*. *Bioorg Med Chem Lett*. 2007;17(24):6678–6681. <https://doi.org/10.1016/j.bmcl.2007.10.072>.
- Babitskaya VG, Shcherba VV, Ikonnikova NV. Melanin complex of the fungus *Inonotus obliquus*. *Prikl Biokhim Mikrobiol*. 2000;36(4):444.
- Mizuno T, Zhuang C, Abe K, et al. Antitumor and hypoglycemic activities of polysaccharides from the sclerotia and mycelia of *Inonotus obliquus* (Pers.: Fr.) pil. (Aphyllphoromycetidae). *Int J Med Mushrooms*. 1999;1(4):301–316. <https://doi.org/10.1615/IntJMedMushr>.
- Rhee SJ, Cho SY, Kim KM, Cha DS, Park HJ. A comparative study of analytical methods for alkali-soluble β -glucan in medicinal mushroom, Chaga (*Inonotus obliquus*). *LWT - Food Sci Technol (Lebensmittel-Wissenschaft -Technol)*. 2008;41(3):545–549. <https://doi.org/10.1016/j.lwt.2007.03.028>.
- Ma L, Chen H, Zhu W, Wang Z. Effect of different drying methods on physicochemical properties and antioxidant activities of polysaccharides extracted from mushroom *Inonotus obliquus*. *Food Res Int*. 2013;50(2):633–640. <https://doi.org/10.1016/j.foodres.2011.05.005>.
- Lemieszek MK, Langner E, Kaczor J, et al. Anticancer effects of fraction isolated from fruiting bodies of chaga medicinal mushroom, *Inonotus obliquus* (Pers.: Fr.) Pilát (aphyllphoromycetidae): in vitro studies. *Int J Med Mushrooms*. 2011;13(2):131–143. <https://doi.org/10.1615/IntJMedMushr>.
- Lee JH, Hyun CK. Insulin-sensitizing and beneficial lipid-metabolic effects of the water-soluble melanin complex extracted from *Inonotus obliquus*. *Phyther Res*. 2014;28(9):1320–1328. <https://doi.org/10.1002/ptr.5131>.
- Szychowski KA, Rybczyńska-Tkaczyk K, Tobiasz J, Yelnytska-Stawasz V, Pomianek T, Gmiński J. Biological and anticancer properties of *Inonotus obliquus* extracts. *Process Biochem*. 2018;73(June):180–187. <https://doi.org/10.1016/j.procbio.2018.07.015>.
- Géry A, Dubreule C, André V, et al. Chaga (*Inonotus obliquus*), a future potential medicinal fungus in oncology? A chemical study and a comparison of the cytotoxicity against human lung adenocarcinoma cells (A549) and human bronchial epithelial cells (BEAS-2B). *Integr Canc Ther*. 2018;17(3):832–843. <https://doi.org/10.1177/1534735418757912>.
- Nakajima Y, Nishida H, Matsugo S, Konishi T. Cancer cell cytotoxicity of extracts and small phenolic compounds from Chaga [*Inonotus obliquus* (persoon) Pilat]. *J Med Food*. 2009;12(3):501–507. <https://doi.org/10.1089/jmf.2008.1149>.
- Nguyet TMN, Lomunova M, Le BV, et al. The mast cell stabilizing activity of Chaga mushroom critical for its therapeutic effect on food allergy is derived from inotodiol. *Int Immunopharm*. November 2017;2018(54):286–295. <https://doi.org/10.1016/j.intimp.2017.11.025>.
- Zou C-X, Wang X-B, Lv T-M, et al. Flavan derivative enantiomers and drimane sesquiterpene lactones from the *Inonotus obliquus* with neuroprotective effects. *Bioorg Chem*. December 2019;2020:103588. <https://doi.org/10.1016/j.bioorg.2020.103588>, 96.
- Sagayama K, Tanaka N, Fukumoto T, Kashiwada Y. Lanostane-type triterpenes from the sclerotium of *Inonotus obliquus* (Chaga mushrooms) as proliferative agents on human follicle dermal papilla cells. *J Nat Med*. 2019;73(3):597–601. <https://doi.org/10.1007/s11418-019-01280-0>.
- Van Q, Nayak BN, Reimer M, Jones PJH, Fulcher RG, Rempel CB. Anti-inflammatory effect of *Inonotus obliquus*, *Polygala senega* L., and *Viburnum trilobum* in a cell screening assay. *J Ethnopharmacol*. 2009;125(3):487–493. <https://doi.org/10.1016/j.jep.2009.06.026>.
- Wang J, Hu W, Li L, et al. Antidiabetic activities of polysaccharides separated from *Inonotus obliquus* via the modulation of oxidative stress in mice with streptozotocin-induced diabetes. *PLoS One*. 2017;12(6):1–19. <https://doi.org/10.1371/journal.pone.0180476>.
- Fan L, Ding S, Ai L, Deng K. Antitumor and immunomodulatory activity of water-soluble polysaccharide from *Inonotus obliquus*. *Carbohydr Polym*. 2012;90(2):870–874. <https://doi.org/10.1016/j.carbpol.2012.06.013>.
- Ichimura T, Watanabe O, Maruyama S. Inhibition of HIV-1 protease by water-soluble lignin-like substance from an edible mushroom, *Fuscoporia obliqua*. *Biosci Biotechnol Biochem*. 1998;62(3):575–577. <https://doi.org/10.1271/bbb.62.575>.
- Hu H, Zhang Z, Lei Z, Yang Y, Sugiura N. Comparative study of antioxidant activity and antiproliferative effect of hot water and ethanol extracts from the mushroom *Inonotus obliquus*. *J Biosci Bioeng*. 2009;107(1):42–48. <https://doi.org/10.1016/j.jbiosc.2008.09.004>.
- Javed S, Mitchell K, Sidsworth D, et al. *Inonotus obliquus* attenuates histamine-induced microvascular inflammation. *PLoS One*. 2019;14(8):1–16. <https://doi.org/10.1371/journal.pone.0220776>.
- Gao X, Santhanam RK, Xue Z, et al. Antioxidant, α -amylase and α -glucosidase activity of various solvent fractions of *I. obliquus* and the preventive role of active fraction against H₂O₂ induced damage in hepatic L02 cells as fungisome. *J Food Sci*. 2020;85(4):1060–1069. <https://doi.org/10.1111/1750-3841.15084>.
- Youn M-J, Kim J-K, Park S-Y, et al. Chaga mushroom (*Inonotus obliquus*) induces G0/G1 arrest and apoptosis in human hepatoma HepG2 cells. *World J*

- Gastroenterol.* 2008;14(4):511–517. <https://doi.org/10.3748/wjg.14.511>.
44. Youn MJ, Kim JK, yeol Park S, et al. Potential anticancer properties of the water extract of *Inonotus obliquus* by induction of apoptosis in melanoma B16-F10 cells. *J Ethnopharmacol.* 2009;121(2):221–228. <https://doi.org/10.1016/j.jep.2008.10.016>.
 45. Tsai CC, Li YS, Lin PP. *Inonotus obliquus* extract induces apoptosis in the human colorectal carcinoma's HCT-116 cell line. *Biomed Pharmacother.* 2017;96(1018):1119–1126. <https://doi.org/10.1016/j.biopha.2017.11.111>.
 46. Lee HS, Kim EJ, Kim SH. Ethanol extract of *Inonotus obliquus* (Chaga mushroom) induces G1 cell cycle arrest in HT-29 human colon cancer cells. *Nutr Res Pract.* 2015;9(2):111. <https://doi.org/10.4162/nrp.2015.9.2.111>.
 47. Zhao F, Xia G, Chen L, et al. Chemical constituents from *Inonotus obliquus* and their antitumor activities. *J Nat Med.* 2016;70(4):721–730. <https://doi.org/10.1007/s11418-016-1002-4>.
 48. Liu Z, Yu D, Li L, et al. Three-phase partitioning for the extraction and purification of polysaccharides from the immunomodulatory medicinal mushroom *Inonotus obliquus*. *Molecules.* 2019;24(3):1–14. <https://doi.org/10.3390/molecules24030403>.
 49. Chung MJ, Chung C-K, Jeong Y, Ham S-S. Anticancer activity of subfractions containing pure compounds of Chaga mushroom (*Inonotus obliquus*) extract in human cancer cells and in Balb/c mice bearing Sarcoma-180 cells. *Nutr Res Pract.* 2010;4(3):177–182. <https://doi.org/10.4162/nrp.2010.4.3.177>.
 50. Burmasova MA, Utebaeva AA, Sysoeva EV, Sysoeva MA. Melanins of *Inonotus obliquus*: bifidogenic and antioxidant properties. *Biomolecules.* 2019;9(6):1–9. <https://doi.org/10.3390/biom9060248>.
 51. Zhang S-D, Yu L, Wang P, et al. Inotodiol inhibits cells migration and invasion and induces apoptosis via p53-dependent pathway in HeLa cells. *Phytomedicine.* 2019;60(May):152957. <https://doi.org/10.1016/j.phymed.2019.152957>.
 52. Frye LL, Leonard DA. Lanosterol analogs: dual-action inhibitors of cholesterol biosynthesis. *Crit Rev Biochem Mol Biol.* 1999;34(2):123–140. <https://doi.org/10.1080/10409239991209246>.
 53. Wold CW, Gerwick WH, Wangenstein H, Inngjerdingen KT. Bioactive triterpenoids and water-soluble melanin from *Inonotus obliquus* (Chaga) with immunomodulatory activity. *J Funct Foods.* 2020;71(March):104025. <https://doi.org/10.1016/j.jff.2020.104025>.
 54. Zou CX, Hou ZL, Bai M, et al. Highly modified steroids from *Inonotus obliquus*. *Org Biomol Chem.* 2020;18(20):3908–3916. <https://doi.org/10.1039/d0ob00474j>.
 55. Wang C, Chen Z, Pan Y, Gao X, Chen H. Anti-diabetic effects of *Inonotus obliquus* polysaccharides-chromium (III) complex in type 2 diabetic mice and its sub-acute toxicity evaluation in normal mice. *Food Chem Toxicol.* 2017;108:498–509. <https://doi.org/10.1016/j.fct.2017.01.007>.
 56. Wang J, Wang C, Li S, et al. Anti-diabetic effects of *Inonotus obliquus* polysaccharides in streptozotocin-induced type 2 diabetic mice and potential mechanism via PI3K-Akt signal pathway. *Biomed Pharmacother.* 2017;95:1669–1677. <https://doi.org/10.1016/j.biopha.2017.09.104>.
 57. Hu Y, Sheng Y, Yu M, et al. Antioxidant activity of *Inonotus obliquus* polysaccharide and its amelioration for chronic pancreatitis in mice. *Int J Biol Macromol.* 2016;87:348–356. <https://doi.org/10.1016/j.ijbiomac.2016.03.006>.
 58. Sim YC, Lee JS, Lee S, et al. Effects of polysaccharides isolated from *Inonotus obliquus* against hydrogen peroxide-induced oxidative damage in RINm5F pancreatic cells. *Mol Med Rep.* 2016;14(5):4263–4270. <https://doi.org/10.3892/mmr.2016.5763>.
 59. Hu Y, Shi S, Lu L, et al. Effects of selenizing modification on characteristics and antioxidant activities of *Inonotus obliquus* polysaccharide. *Macromol Res.* 2017;25(3):222–230. <https://doi.org/10.1007/s13233-017-5030-z>.
 60. Wang C, Li W, Chen Z, et al. Effects of simulated gastrointestinal digestion in vitro on the chemical properties, antioxidant activity, α -amylase and α -glucosidase inhibitory activity of polysaccharides from *Inonotus obliquus*. *Food Res Int.* July 2017;2018(103):280–288. <https://doi.org/10.1016/j.foodres.2017.12.058>.
 61. Niu H, Song D, Mu H, Zhang W, Sun F, Duan J. Investigation of three lignin complexes with antioxidant and immunological capacities from *Inonotus obliquus*. *Int J Biol Macromol.* 2016;86:587–593. <https://doi.org/10.1016/j.ijbiomac.2016.01.111>.
 62. Wold CW, Kjeldsen C, Corthay A, et al. Structural characterization of bioactive heteropolysaccharides from the medicinal fungus *Inonotus obliquus* (Chaga). *Carbohydr Polym.* December 2017;2018(185):27–40. <https://doi.org/10.1016/j.carbpol.2017.12.041>.
 63. Xu L, Sang R, Yu Y, Li J, Ge B, Zhang X. The polysaccharide from *Inonotus obliquus* protects mice from *Toxoplasma gondii*-induced liver injury. *Int J Biol Macromol.* 2019;125:1–8. <https://doi.org/10.1016/j.ijbiomac.2018.11.114>.
 64. Xu L, Yu Y, Sang R, et al. *Inonotus obliquus* polysaccharide protects against adverse pregnancy caused by *Toxoplasma gondii* infection through regulating Th17/Treg balance via TLR4/NF- κ B pathway. *Int J Biol Macromol.* 2020;146:832–840. <https://doi.org/10.1016/j.ijbiomac.2019.10.051>.
 65. Ding X, Ge B, Wang M, et al. *Inonotus obliquus* polysaccharide ameliorates impaired reproductive function caused by *Toxoplasma gondii* infection in male mice via regulating Nrf2-PI3K/AKT pathway. *Int J Biol Macromol.* 2020;151:449–458. <https://doi.org/10.1016/j.ijbiomac.2020.02.178>.
 66. Han Y, Nan S, Fan J, Chen Q, Zhang Y. *Inonotus obliquus* polysaccharides protect against Alzheimer's disease by regulating Nrf2 signaling and exerting antioxidative and antiapoptotic effects. *Int J Biol Macromol.* 2019;131:769–778. <https://doi.org/10.1016/j.ijbiomac.2019.03.033>.
 67. Jiang S, Shi F, Lin H, et al. *Inonotus obliquus* polysaccharides induces apoptosis of lung cancer cells and alters energy metabolism via the LKB1/AMPK axis. *Int J Biol Macromol.* 2020;151:1277–1286. <https://doi.org/10.1016/j.ijbiomac.2019.10.174>.
 68. Kim YO, Park HW, Kim JH, Lee JY, Moon SH, Shin CS. Anti-cancer effect and structural characterization of endo-polysaccharide from cultivated mycelia of *Inonotus obliquus*. *Life Sci.* 2006;79(1):72–80. <https://doi.org/10.1016/j.lfs.2005.12.047>.
 69. Eid JI, Das B. Molecular insights and cell cycle assessment upon exposure to Chaga (*Inonotus obliquus*) mushroom polysaccharides in zebrafish (*Danio rerio*). *Sci Rep.* 2020;10(1):7406. <https://doi.org/10.1038/s41598-020-64157-3>.
 70. Hwang BS, Lee I-K, Yun B-S. Phenolic compounds from the fungus *Inonotus obliquus* and their antioxidant properties. *J Antibiot (Tokyo).* 2016;69(2):108–110. <https://doi.org/10.1038/ja.2015.83>.
 71. Zhang CJ, Guo JY, Cheng H, et al. Spatial structure and anti-fatigue of polysaccharide from *Inonotus obliquus*. *Int J Biol Macromol.* 2020;151:855–860. <https://doi.org/10.1016/j.ijbiomac.2020.02.147>.
 72. Seo DJ, Choi C. Inhibition of murine norovirus and feline calicivirus by edible herbal extracts. *Food Environ Virol.* 2017;9(1):35–44. <https://doi.org/10.1007/s12560-016-9269-x>.
 73. Tian J, Hu X, Liu D, Wu H, Qu L. Identification of *Inonotus obliquus* polysaccharide with broad-spectrum antiviral activity against multi-feline viruses. *Int J Biol Macromol.* 2017;95:160–167. <https://doi.org/10.1016/j.ijbiomac.2016.11.054>.
 74. Zheng W, Miao K, Liu Y, et al. Chemical diversity of biologically active metabolites in the sclerotia of *Inonotus obliquus* and submerged culture strategies for up-regulating their production. *Appl Microbiol Biotechnol.* 2010;87(4):1237–1254. <https://doi.org/10.1007/s00253-010-2682-4>.
 75. Zhang X, Bao C, Zhang J. Inotodiol suppresses proliferation of breast cancer in rat model of type 2 diabetes mellitus via downregulation of β -catenin signaling. *Biomed Pharmacother.* 2018;99:142–150. <https://doi.org/10.1016/j.biopha.2017.12.084>.
 76. Xu H-Y, Sun J-E, Lu Z-M, Zhang X-M, Dou W-F, Xu Z-H. Beneficial effects of the ethanol extract from the dry matter of a culture broth of *Inonotus obliquus* in submerged culture on the antioxidant defence system and regeneration of pancreatic β -cells in experimental diabetes in mice. Intergovernmental Panel on Climate Change. *Nat Prod Res.* 2010;24(6):542–553. <https://doi.org/10.1080/14786410902751009>.
 77. Wang C, Gao X, Santhanam RK, et al. Effects of polysaccharides from *Inonotus obliquus* and its chromium (III) complex on advanced glycation end-products formation, α -amylase, α -glucosidase activity and H2O2-induced oxidative damage in hepatic L02 cells. *Food Chem Toxicol.* 2018;116(February):335–345. <https://doi.org/10.1016/j.fct.2018.04.047>.
 78. Yong T, Chen S, Liang D, et al. Actions of *Inonotus obliquus* against hyperuricemia through XOD and bioactives screened by molecular modeling. *Int J Mol Sci.* 2018;19(10):1–11. <https://doi.org/10.3390/ijms19103222>.
 79. Xu X, Wu P, Wang T, Yan L, Lin M, Chen C. Synergistic effects of surfactant-assisted biodegradation of wheat straw and production of polysaccharides by *Inonotus obliquus* under submerged fermentation. *Bioresour Technol.* November 2018;2019(278):43–50. <https://doi.org/10.1016/j.biortech.2019.01.022>.
 80. Niu H, Song D, Mu H, Zhang W, Sun F, Duan J. Investigation of three lignin complexes with antioxidant and immunological capacities from *Inonotus obliquus*. *Int J Biol Macromol.* 2016;86:587–593. <https://doi.org/10.1016/j.ijbiomac.2016.01.111>.
 81. Liang L, Zhang Z, Wang H. Antioxidant activities of extracts and subfractions from *Inonotus Obliquus*. *Int J Food Sci Nutr.* 2009;60(sup2):175–184. <https://doi.org/10.1080/09637480903042279>.
 82. Nakajima Y, Nishida H, Nakamura Y, Konishi T. Prevention of hydrogen peroxide-induced oxidative stress in PC12 cells by 3,4-dihydroxybenzalacetone isolated from Chaga (*Inonotus obliquus* (persoon) Pilat). *Free Radic Biol Med.* 2009;47(8):1154–1161. <https://doi.org/10.1016/j.freeradbiomed.2009.07.029>.
 83. Yun JS, Pahk JW, Lee JS, Shin WC, Lee SY, Hon EK. *Inonotus obliquus* protects against oxidative stress-induced apoptosis and premature senescence. *Mol Cell.* 2011;31(5):423–429. <https://doi.org/10.1007/s10059-011-0256-7>.
 84. Huang S quan, Ding S, Fan L. Antioxidant activities of five polysaccharides from *Inonotus obliquus*. *Int J Biol Macromol.* 2012;50(5):1183–1187. <https://doi.org/10.1016/j.ijbiomac.2012.03.019>.
 85. Mu H, Zhang A, Zhang W, Cui G, Wang S, Duan J. Antioxidative properties of crude polysaccharides from *Inonotus obliquus*. *Int J Mol Sci.* 2012;13(7):9194–9206. <https://doi.org/10.3390/ijms13079194>.
 86. Debnath T, Park SR, Kim DH, Jo JE, Lim BO. Anti-oxidant and anti-inflammatory activities of *Inonotus obliquus* and germinated brown rice extracts. *Molecules.* 2013;18(8):9293–9304. <https://doi.org/10.3390/molecules18089293>.
 87. Du XJ, Mu HM, Zhou S, Zhang Y, Zhu XL. Chemical analysis and antioxidant activity of polysaccharides extracted from *Inonotus obliquus* sclerotia. *Int J Biol Macromol.* 2013;62:691–696. <https://doi.org/10.1016/j.ijbiomac.2013.10.016>.
 88. Zhang L, Lin D, Li H, et al. Immunopotentiating effect of *Inonotus obliquus* fermentation products administered at vaccination in chickens. *Mol Cell Probes.* 2018;41(July):43–51. <https://doi.org/10.1016/j.mcp.2018.09.002>.
 89. Chen YF, Zheng JJ, Qu C, et al. *Inonotus obliquus* polysaccharide ameliorates

- dextran sulphate sodium induced colitis involving modulation of Th1/Th2 and Th17/Treg balance. *Artif Cells Nanomed Biotechnol.* 2019;47(1):757–766. <https://doi.org/10.1080/21691401.2019.1577877>.
90. Kim Y-R. Immunomodulatory activity of the water extract from medicinal mushroom *Inonotus obliquus*. *Mycobiology.* 2005;33(3):158–162. <https://doi.org/10.4489/MYCO>.
 91. Choi SY, Hur SJ, An CS, et al. Anti-inflammatory effects of *Inonotus obliquus* in colitis induced by dextran sodium sulfate. *J Biomed Biotechnol.* 2010;2010:943516. <https://doi.org/10.1155/2010/943516>.
 92. Gunjima K, Tomiyama R, Takakura K, et al. 3,4-dihydroxybenzalacetone protects against Parkinson's disease-related neurotoxin 6-OHDA through Akt/Nrf2/glutathione pathway. *J Cell Biochem.* 2014;115(1):151–160. <https://doi.org/10.1002/jcb.24643>.
 93. Lee KR, Lee JS, Lee S, et al. Polysaccharide isolated from the liquid culture broth of *Inonotus obliquus* suppresses invasion of B16-F10 melanoma cells via AKT/NFB signaling pathway. *Mol Med Rep.* 2016;14(5):4429–4435. <https://doi.org/10.3892/mmr.2016.5771>.
 94. Nomura M, Takahashi T, Uesugi A, Tanaka R, Kobayashi S. Inotodiol, a lanostane triterpenoid, from *Inonotus obliquus* inhibits cell proliferation through caspase-3-dependent apoptosis. *Anticancer Res.* 2008;28(5 A):2691–2696.
 95. Baek J, Roh H-S, Baek K-H, et al. Bioactivity-based analysis and chemical characterization of cytotoxic constituents from Chaga mushroom (*Inonotus obliquus*) that induce apoptosis in human lung adenocarcinoma cells. *J Ethnopharmacol.* 2018;224:63–75. <https://doi.org/10.1016/j.jep.2018.05.025>.
 96. Fu L, Chen H, Dong P, Zhang X, Zhang M. Effects of ultrasonic treatment on the physicochemical properties and DPPH radical scavenging activity of polysaccharides from mushroom *Inonotus obliquus*. *J Food Sci.* 2010;75(4):C322–C327. <https://doi.org/10.1111/j.1750-3841.2010.01590.x>.
 97. Xiang Y, Xu X, Li J. Chemical properties and antioxidant activity of exopolysaccharides fractions from mycelial culture of *Inonotus obliquus* in a ground corn stover medium. *Food Chem.* 2012;134(4):1899–1905. <https://doi.org/10.1016/j.foodchem.2012.03.121>.
 98. Xu X, Wu Y, Chen H. Comparative antioxidative characteristics of polysaccharide-enriched extracts from natural sclerotia and cultured mycelia in submerged fermentation of *Inonotus obliquus*. *Food Chem.* 2011;127(1):74–79. <https://doi.org/10.1016/j.foodchem.2010.12.090>.
 99. Blois MS. Antioxidant determinations by the use of a stable free radical. *Nature.* 1958;181(4617):1199–1200. <https://doi.org/10.1038/1811199a0>.
 100. Floegel A, Kim DO, Chung SJ, Koo SI, Chun OK. Comparison of ABTS/DPPH assays to measure antioxidant capacity in popular antioxidant-rich US foods. *J Food Compos Anal.* 2011;24(7):1043–1048. <https://doi.org/10.1016/j.jfca.2011.01.008>.
 101. Chen Y, Huang Y, Cui Z, Liu J. Purification, characterization and biological activity of a novel polysaccharide from *Inonotus obliquus*. *Int J Biol Macromol.* 2015;79:587–594. <https://doi.org/10.1016/j.ijbiomac.2015.05.016>.
 102. Kapp K, Püssa T, Vuorela H, Välimaa H. Antiviral effect of *Inonotus obliquus* (Pers.:Fr.) Pilat extract against herpes simplex virus type 1 in vitro. 2017. <https://doi.org/10.1055/s-0037-1608419>.
 103. Hu Y, Teng C, Yu S, et al. *Inonotus obliquus* polysaccharide regulates gut microbiota of chronic pancreatitis in mice. *AMB Express.* 2017;7(1):39. <https://doi.org/10.1186/s13568-017-0341-1>.
 104. Montazeri M, Sharif M, Sarvi S, Mehrzadi S, Ahmadpour E, Daryani A. A systematic review of in vitro and in vivo activities of anti-toxoplasma drugs and compounds (2006–2016). *Front Microbiol.* 2017;8(JAN):25. <https://doi.org/10.3389/fmicb.2017.00025>.
 105. Kang J-H, Jang J-E, Mishra SK, et al. Ergosterol peroxide from Chaga mushroom (*Inonotus obliquus*) exhibits anti-cancer activity by down-regulation of the β -catenin pathway in colorectal cancer. *J Ethnopharmacol.* 2015;173:303–312. <https://doi.org/10.1016/j.jep.2015.07.030>.
 106. Lee SH, Hwang HS, Yun JW. Antitumor activity of water extract of a mushroom, *Inonotus obliquus*, against HT-29 human colon cancer cells. *Phyther Res.* 2009;23(12):1784–1789. <https://doi.org/10.1002/ptr.2836>.
 107. Zou C, Zhang Y-Y, Bai M, Huang X-X, Wang X-B, Song S-J. Aromatic compounds from the sclerotia of *Inonotus obliquus*. *Nat Prod Res.* October 2019:1–4. <https://doi.org/10.1080/14786419.2019.1677656>.
 108. Li Z, Mei J, Jiang L, et al. Chaga medicinal mushroom, *Inonotus obliquus* (agaricomycetes) polysaccharides suppress tacrine-induced apoptosis by ROS-scavenging and mitochondrial pathway in HepG2 cells. *Int J Med Mushrooms.* 2019;21(6):583–593. <https://doi.org/10.1615/IntJMedMushrooms.2019030857>.
 109. Wang Q, Mu H, Zhang L, Dong D, Zhang W, Duan J. Characterization of two water-soluble lignin metabolites with antiproliferative activities from *Inonotus obliquus*. *Int J Biol Macromol.* 2015;74(20120731):507–514. <https://doi.org/10.1016/j.ijbiomac.2014.12.044>.
 110. Quintero-Fabian S, Arreola R, Becerril-Villanueva E, et al. Role of matrix metalloproteinases in angiogenesis and cancer. *Front Oncol.* 2019;9(December):1–21. <https://doi.org/10.3389/fonc.2019.01370>.
 111. Lee KR, Lee JS, Song JE, Ha SJ, Hong EK. *Inonotus obliquus*-derived polysaccharide inhibits the migration and invasion of human non-small cell lung carcinoma cells via suppression of MMP-2 and MMP-9. *Int J Oncol.* 2014;45(6):2533–2540. <https://doi.org/10.3892/ijo.2014.2685>.
 112. Arata S, Watanabe J, Maeda M, et al. Continuous intake of the Chaga mushroom (*Inonotus obliquus*) aqueous extract suppresses cancer progression and maintains body temperature in mice. *Heliyon.* 2016;2(5), e00111. <https://doi.org/10.1016/j.heliyon.2016.e00111>.
 113. Duru KC, Kovaleva EG, Danilova IG, Bijl P. The pharmacological potential and possible molecular mechanisms of action of *Inonotus obliquus* from preclinical studies. *Phyther Res.* 2019;33(8):1966–1980. <https://doi.org/10.1002/ptr.6384>.
 114. Koene RJ, Prizment AE, Blaes A, Konety SH. Shared risk factors in cardiovascular disease and cancer. *Circulation.* 2016;133(11):1104–1114. <https://doi.org/10.1161/CIRCULATIONAHA.115.020406>.
 115. Liu P, Xue J, Tong S, Dong W, Wu P. Structure Characterization and Hypoglycaemic Activities of two polysaccharides from *Inonotus obliquus*. *Molecules.* 2018;23(8):1948. <https://doi.org/10.3390/molecules23081948>.
 116. Wang M, Zhao Z, Zhou X, et al. Simultaneous use of stimulatory agents to enhance the production and hypoglycaemic activity of polysaccharides from *Inonotus obliquus* by submerged fermentation. *Molecules.* 2019;24(23):4400. <https://doi.org/10.3390/molecules24234400>.
 117. Diao B, Jin W, Yu X. Protective effect of polysaccharides from *Inonotus obliquus* on streptozotocin-induced diabetic symptoms and their potential mechanisms in rats. *Evid Base Complement Alternat Med.* 2014;2014:841496. <https://doi.org/10.1155/2014/841496>.
 118. Cha JY, Jun BS, Yoo KS, Hahm JR, Cho YS. Fermented chaga mushroom (*Inonotus obliquus*) effects on hypolipidemia and hepatoprotection in Otsuka Long-Evans Tokushima fatty (OLETF) rats. *Food Sci Biotechnol.* 2006;15:122–127.
 119. Sun J-E, Ao Z-H, Lu Z-M, et al. Antihyperglycemic and antilipidperoxidative effects of dry matter of culture broth of *Inonotus obliquus* in submerged culture on normal and alloxan-diabetes mice. *J Ethnopharmacol.* 2008;118(1):7–13. <https://doi.org/10.1016/j.jep.2008.02.030>.
 120. Chou Y-J, Kan W-C, Chang C-M, et al. Renal protective effects of low molecular weight of *Inonotus obliquus* polysaccharide (LIOP) on HFD/STZ-Induced nephropathy in mice. *Int J Mol Sci.* 2016;17(9):1535. <https://doi.org/10.3390/ijms17091535>.
 121. Olefsky JM. Treatment of insulin resistance with peroxisome proliferator-activated receptor γ agonists. *J Clin Invest.* 2000;106(4):467–472. <https://doi.org/10.1172/JCI10843>.
 122. Clark RB. The role of PPARs in inflammation and immunity. *J Leukoc Biol.* 2002;71(3):388–400. <https://doi.org/10.1189/jlb.71.3.388>.
 123. Joo JI, Kim DH, Yun JW. Extract of Chaga mushroom (*Inonotus obliquus*) stimulates 3 β -H α adipocyte differentiation. *Phyther Res.* 2010;24(11):1592–1599. <https://doi.org/10.1002/ptr.3180>.